180 related articles for article (PubMed ID: 8314382)
21. Evaluation of new drugs and combinations in gynecologic tumors and cancer cell lines with the ATP-cell viability assay.
Untch M; Sevin BU
Contrib Gynecol Obstet; 1994; 19():145-55. PubMed ID: 7995046
[No Abstract] [Full Text] [Related]
22. TCA-100 tumour chemosensitivity assay: differences in sensitivity between cultured tumour cell lines and clinical studies.
Andreotti PE; Linder D; Hartmann DM; Cree IA; Pazzagli M; Bruckner HW
J Biolumin Chemilumin; 1994; 9(6):373-8. PubMed ID: 7879653
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of optimal drug concentration in histoculture drug response assay in association with clinical efficacy for head and neck cancer.
Hasegawa Y; Goto M; Hanai N; Ijichi K; Adachi M; Terada A; Hyodo I; Ogawa T; Furukawa T
Oral Oncol; 2007 Sep; 43(8):749-56. PubMed ID: 17112769
[TBL] [Abstract][Full Text] [Related]
24. Survival of patients with limited-stage small cell lung cancer treated with individualized chemotherapy selected by in vitro drug sensitivity testing.
Cortazar P; Gazdar AF; Woods E; Russell E; Steinberg SM; Williams J; Ihde DC; Johnson BE
Clin Cancer Res; 1997 May; 3(5):741-7. PubMed ID: 9815744
[TBL] [Abstract][Full Text] [Related]
25. Cytotoxic drugs efficacy correlates with adipose tissue docosahexaenoic acid level in locally advanced breast carcinoma.
Bougnoux P; Germain E; Chajès V; Hubert B; Lhuillery C; Le Floch O; Body G; Calais G
Br J Cancer; 1999 Apr; 79(11-12):1765-9. PubMed ID: 10206290
[TBL] [Abstract][Full Text] [Related]
26. Carboplatin in combination therapy for metastatic breast cancer.
Perez EA
Oncologist; 2004; 9(5):518-27. PubMed ID: 15477636
[TBL] [Abstract][Full Text] [Related]
27. Feasibility assessment of a chemoresponse assay to predict pathologic response in neoadjuvant chemotherapy for breast cancer patients.
Mi Z; Holmes FA; Hellerstedt B; Pippen J; Collea R; Backner A; Bush JE; Gallion HH; Wells A; O'Shaughnessy JA
Anticancer Res; 2008; 28(3B):1733-40. PubMed ID: 18630452
[TBL] [Abstract][Full Text] [Related]
28. The molecular basis of the chemosensitivity of metastatic cutaneous melanoma to chemotherapy.
Parker KA; Glaysher S; Polak M; Gabriel FG; Johnson P; Knight LA; Poole M; Narayanan A; Hurren J; Cree IA
J Clin Pathol; 2010 Nov; 63(11):1012-20. PubMed ID: 20924094
[TBL] [Abstract][Full Text] [Related]
29. [Current trends in pharmacotherapy of breast cancer].
Boér K
Orv Hetil; 2002 Apr; 143(14):725-30. PubMed ID: 11975393
[TBL] [Abstract][Full Text] [Related]
30. Rationale for sequential tamoxifen and anticancer drugs in adjuvant setting for patients with node- and receptor-positive breast cancer.
Kim R; Tanabe K; Emi M; Uchida Y; Osaki A; Toge T
Int J Oncol; 2005 Apr; 26(4):1025-31. PubMed ID: 15753998
[TBL] [Abstract][Full Text] [Related]
31. Effect of culture conditions on the chemosensitivity of ovarian cancer cell lines.
Fernando A; Glaysher S; Conroy M; Pekalski M; Smith J; Knight LA; Di Nicolantonio F; Cree IA
Anticancer Drugs; 2006 Sep; 17(8):913-9. PubMed ID: 16940801
[TBL] [Abstract][Full Text] [Related]
32. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy.
Li X; Lewis MT; Huang J; Gutierrez C; Osborne CK; Wu MF; Hilsenbeck SG; Pavlick A; Zhang X; Chamness GC; Wong H; Rosen J; Chang JC
J Natl Cancer Inst; 2008 May; 100(9):672-9. PubMed ID: 18445819
[TBL] [Abstract][Full Text] [Related]
33. Combined chemotherapy and preoperative irradiation for locally advanced noninflammatory breast cancer: updated results in a series of 120 patients.
Lerouge D; Touboul E; Lefranc JP; Genestie C; Moureau-Zabotto L; Blondon J
Int J Radiat Oncol Biol Phys; 2004 Jul; 59(4):1062-73. PubMed ID: 15234040
[TBL] [Abstract][Full Text] [Related]
34. Clinical applications of the histoculture drug response assay.
Furukawa T; Kubota T; Hoffman RM
Clin Cancer Res; 1995 Mar; 1(3):305-11. PubMed ID: 9815986
[TBL] [Abstract][Full Text] [Related]
35. Adjuvant therapy for breast cancer.
NIH Consens Statement; 2000 Nov 1-3; 17(4):1-35. PubMed ID: 11512506
[TBL] [Abstract][Full Text] [Related]
36. A radiometric method for evaluation of chemotherapy sensitivity: results of screening a panel of human breast cancer cell lines.
Arteaga CL; Forseth BJ; Clark GM; Von Hoff DD
Cancer Res; 1987 Dec; 47(23):6248-53. PubMed ID: 3119196
[TBL] [Abstract][Full Text] [Related]
37. Vinorelbine and cisplatin (CIVIC regimen) for the treatment of metastatic breast carcinoma after failure of anthracycline- and/or paclitaxel-containing regimens.
Ray-Coquard I; Biron P; Bachelot T; Guastalla JP; Catimel G; Merrouche Y; Droz JP; Chauvin F; Blay JY
Cancer; 1998 Jan; 82(1):134-40. PubMed ID: 9428489
[TBL] [Abstract][Full Text] [Related]
38. [Predictive value of in vitro MTT assay chemosensitivity test of cytotoxic drug activity in cervical cancer].
Xiao Y; Li JD; Shi HL; Liu JH; Feng YL; Li MD
Ai Zheng; 2007 Apr; 26(4):386-9. PubMed ID: 17430657
[TBL] [Abstract][Full Text] [Related]
39. Evolving concepts in the systemic drug therapy of breast cancer.
Norton L
Semin Oncol; 1997 Aug; 24(4 Suppl 10):S10-3-S10-10. PubMed ID: 9275000
[TBL] [Abstract][Full Text] [Related]
40. [Results of antineoplastic chemotherapy based on the oncobiogram].
Ebert A; Lenk H; Geyer J; Tanneberger S
Arch Geschwulstforsch; 1989; 59(6):455-61. PubMed ID: 2596959
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
